Search research articles
Contact Us
Filters
Showing results (451-460 of 583) with videos related to
Page
of 59
Sort By:
Blood
|
June 5, 2010
P-glycoprotein inhibition using valspodar (PSC-833) does not improve outcomes for patients younger than age 60 years with newly diagnosed acute myeloid leukemia: Cancer and Leukemia Group B study 19808
Jonathan E Kolitz, Stephen L George, Guido Marcucci, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 20, 2009
Prognostic importance of MN1 transcript levels, and biologic insights from MN1-associated gene and microRNA expression signatures in cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study
Christian Langer, Guido Marcucci, Kelsi B Holland, et al.
Annals of Hematology
|
May 6, 2004
Core binding factor acute myeloid leukemia. Cancer and Leukemia Group B (CALGB) Study 8461
C D Bloomfield, A S Ruppert, K Mrózek, et al.
Blood
|
January 12, 2008
MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia
Ramiro Garzon, Stefano Volinia, Chang-Gong Liu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 19, 2008
Wilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study
Peter Paschka, Guido Marcucci, Amy S Ruppert, et al.
Cancer Discovery
|
June 30, 2016
Dissection of the Major Hematopoietic Quantitative Trait Locus in Chromosome 6q23.3 Identifies miR-3662 as a Player in Hematopoiesis and Acute Myeloid Leukemia
Sophia E Maharry, Christopher J Walker, Sandya Liyanarachchi, et al.
Blood
|
March 9, 2006
Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461
, Sherif S Farag, Kellie J Archer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 7, 2012
Bortezomib added to daunorubicin and cytarabine during induction therapy and to intermediate-dose cytarabine for consolidation in patients with previously untreated acute myeloid leukemia age 60 to 75 years: CALGB (Alliance) study 10502
Eyal C Attar, Jeffrey L Johnson, Philip C Amrein, et al.
Leukemia
|
March 23, 2018
Mutation patterns identify adult patients with de novo acute myeloid leukemia aged 60 years or older who respond favorably to standard chemotherapy: an analysis of Alliance studies
Ann-Kathrin Eisfeld, Jessica Kohlschmidt, Krzysztof Mrózek, et al.
Blood
|
May 10, 2007
Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel
Ayalew Tefferi, Juergen Thiele, Attilio Orazi, et al.
Page
of 59
Search research articles
Search
Showing results (451-460 of 583) with videos related to
Sort By:
Page
of 59
Blood
|
June 5, 2010
P-glycoprotein inhibition using valspodar (PSC-833) does not improve outcomes for patients younger than age 60 years with newly diagnosed acute myeloid leukemia: Cancer and Leukemia Group B study 19808
Jonathan E Kolitz, Stephen L George, Guido Marcucci, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 20, 2009
Prognostic importance of MN1 transcript levels, and biologic insights from MN1-associated gene and microRNA expression signatures in cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study
Christian Langer, Guido Marcucci, Kelsi B Holland, et al.
Annals of Hematology
|
May 6, 2004
Core binding factor acute myeloid leukemia. Cancer and Leukemia Group B (CALGB) Study 8461
C D Bloomfield, A S Ruppert, K Mrózek, et al.
Blood
|
January 12, 2008
MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia
Ramiro Garzon, Stefano Volinia, Chang-Gong Liu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 19, 2008
Wilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study
Peter Paschka, Guido Marcucci, Amy S Ruppert, et al.
Cancer Discovery
|
June 30, 2016
Dissection of the Major Hematopoietic Quantitative Trait Locus in Chromosome 6q23.3 Identifies miR-3662 as a Player in Hematopoiesis and Acute Myeloid Leukemia
Sophia E Maharry, Christopher J Walker, Sandya Liyanarachchi, et al.
Blood
|
March 9, 2006
Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461
, Sherif S Farag, Kellie J Archer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 7, 2012
Bortezomib added to daunorubicin and cytarabine during induction therapy and to intermediate-dose cytarabine for consolidation in patients with previously untreated acute myeloid leukemia age 60 to 75 years: CALGB (Alliance) study 10502
Eyal C Attar, Jeffrey L Johnson, Philip C Amrein, et al.
Leukemia
|
March 23, 2018
Mutation patterns identify adult patients with de novo acute myeloid leukemia aged 60 years or older who respond favorably to standard chemotherapy: an analysis of Alliance studies
Ann-Kathrin Eisfeld, Jessica Kohlschmidt, Krzysztof Mrózek, et al.
Blood
|
May 10, 2007
Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel
Ayalew Tefferi, Juergen Thiele, Attilio Orazi, et al.
Page
of 59